ELAVL1 and thyroid cancer: Considering HuR overexpression in thyroid cancer tissues as well as the results obtained by HuR silencing, indicating a HuR-dependent mechanism of thyroid cancer cell survival, this RBP might be consider an innovative therapeutic target for thyroid cancer.